Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

ARRY 5.81 +0.06 (1.04%)
price chart
Zacks Rating on Array BioPharma Inc.
Array BioPharma Inc. (NASDAQ:ARRY) remains a strong buy in the latest set of rankings. The shares have received an average rating of 1 by 7 analysts.
Stock Update - Array BioPharma Inc. (NASDAQ:ARRY)  Vanguard Tribune
Array BioPharma Inc. (NASDAQ:ARRY) Short Interest Update  Insider Trading Report
Company Shares of Array BioPharma Inc. Drops by -10.55%
Array BioPharma Inc. (NASDAQ:ARRY) has lost 10.55% during the past week and dropped 16.69% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 8.53%.
Downward Movements - Array Biopharma Inc (ARRY), Peabody Energy Corporation ...  Techsonian (press release)
Array Biopharma Cut to "Sell" at Zacks (ARRY)  The Legacy
Analyst Rating Update on Array BioPharma Inc.
Array Biopharma Inc (NASDAQ:ARRY) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 1 by 7 Wall Street Analysts.
Array Biopharma Inc. (NASDAQ:ARRY) announced that its Chief Executive ...  Inside Trade
Investment Analysts' Weekly Ratings Changes for Array Biopharma (ARRY)  Dakota Financial News
Why Shares in Array BioPharma, Inc. Are Soaring Higher
What: Shares in Array BioPharma (NASDAQ:ARRY) are rallying by more than 10% after the company released its first quarter financial results and offered up insight into its pipeline.
Cantor Fitzgerald Remains Positive on Array Biopharma Inc Following ...  Smarter Analyst
Trade-Ideas: Array BioPharma (ARRY) Is Today's "Dead Cat Bounce ...
Array Biopharma (ARRY) Set to Announce Earnings on Monday
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer.
Array BioPharma Inc. (NASDAQ:ARRY) Analyst Rating Update
Array BioPharma Inc. (NASDAQ:ARRY) shares are expected to touch $11 in the short term. This short term price target has been shared by 6 analysts.
Stock Insights: Array BioPharma Inc. (NASDAQ:ARRY)  Vanguard Tribune
Biotech Stocks leaving investors heartbroken - Galena Biopharma Inc (NASDAQ ...  Wall Street Observer
Short Interest Update of Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. (NASDAQ:ARRY) has witnessed a drop of 4.4% or 1,244,866 shares in its short figure. The short interest diminution took it from 28,079,742 on June 15,2015 to 26,834,876 on June 30,2015.
Company Shares of Array BioPharma Inc. Drops by -0.73%  Insider Trading Report
Today's Hot List: Array BioPharma Inc. (NASDAQ:ARRY), Twenty-First ...  Stock Transcript
Insider Selling: Array Biopharma Inc (NASDAQ:ARRY)'s director Charles Baum ...
Charles Baum, the well informed person, who's the present director of Array Biopharma Inc (NASDAQ:ARRY) 6.19 -0.40 -6.07% sold roughly 25,000 shares of the firm worth roughly $184,483 U.S.
Time To Ring The Register On These Hot Biotech Plays - Array Biopharma (ARRY ...  Wall Street Observer
Array BioPharma Inc. Analyst Price Target Update
Array BioPharma Inc. (NASDAQ:ARRY) shares are expected to touch $11 in the short term. This short term price target has been shared by 6 analysts.
Biotech Stocks That Should Be on Your Watchlist - Array Biopharma Inc (NASDAQ ...
Array Biopharma Inc (NASDAQ:ARRY) fell -1.37% to close last trading session at $5.76. The company, on July 27, 2015, announced that it will report financial results for the fourth quarter and full year of fiscal 2015 and hold a conference call to ...